Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Adicet Bio, Inc.ACET · Entity 6860 | Director · Chief Medical Officer | August 05, 2026 | August 07, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Adicet Bio, Inc.
Report date August 05, 2026 · Filed August 07, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.16 · Expires 2036-08-04 | Direct | 18,300 |
Reported balance
After 2026-08-05 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-08-05 · Grant · Acquired 18,300 · Balance 18,300 F1: 1/6th of the shares subject to this option shall vest and become exercisable on each of the next six (6) monthly anniversaries of August 5, 2026, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting dates. |
Filing footnotes · ownership attribution and instrument terms
F1: 1/6th of the shares subject to this option shall vest and become exercisable on each of the next six (6) monthly anniversaries of August 5, 2026, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting dates.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 05, 2026 Filed Aug 7, 2026 20:01 UTC | Adicet Bio, Inc. ACET · Entity 6860 | GrantStock Option (Right to Buy) · Derivative | 18,300 | $0.00 Strike: $9.16 | $0.00 |
DisclosureSEC source: 0001776004-26-000003 · ownership.xml · derivative · entry 1 Klickstein Lloyd · CIK 0001776004 · Director · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,300 Underlying: Common Stock · 18,300 shares Expires 2036-08-04 F1 · derivative.exercise_date: 1/6th of the shares subject to this option shall vest and become exercisable on each of the next six (6) monthly anniversaries of August 5, 2026, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting dates. Read SEC document |
| June 21, 2026 Filed Jun 23, 2026 20:25 UTC | Adicet Bio, Inc. ACET · Entity 6860 | GrantStock Option (Right to Buy) · Derivative | 4,200 | $0.00 Strike: $8.10 | $0.00 |
DisclosureSEC source: 0001776004-26-000001 · ownership.xml · derivative · entry 1 Klickstein Lloyd · CIK 0001776004 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,200 Underlying: Common Stock · 4,200 shares Expires 2036-06-20 F1 · derivative.exercise_date: These shares shall vest in full on the earlier to occur of (i) the first anniversary of the grant date or (ii) the date of the next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service on the Issuer's board of directors. Read SEC document |
| June 11, 2025 Filed Jun 13, 2025 20:09 UTC | Adicet Bio, Inc. ACET · Entity 6860 | GrantStock Option (Right to Buy) · Derivative | 26,400 | $0.00 Strike: $0.78 | $0.00 |
DisclosureSEC source: 0000950170-25-086166 · ownership.xml · derivative · entry 2 Klickstein Lloyd · CIK 0001776004 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,400 Underlying: Common Stock · 26,400 shares Expires 2035-06-10 F2 · derivative.exercise_date: These shares shall vest in full on the earlier to occur of (i) the first anniversary of the grant date or (ii) the date of the next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service on the Issuer's board of directors. Read SEC document |
| June 11, 2025 Filed Jun 13, 2025 20:09 UTC | Adicet Bio, Inc. ACET · Entity 6860 | GrantCommon Stock | 5,900 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-086166 · ownership.xml · nonDerivative · entry 1 Klickstein Lloyd · CIK 0001776004 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 108,566 F1 · shares: The Reporting Person was issued Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of Common Stock. The RSUs shall vest in full on the earlier to occur of (i) the first anniversary of the grant date or (ii) the date of the next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service on the Issuer's board of directors. The RSUs may be settled only by delivering shares of Common Stock, and thus, the grant is being reported in Table I as allowed per SEC guidance. Read SEC document |
| August 19, 2024 Filed Aug 20, 2024 20:05 UTC | Adicet Bio, Inc. ACET · Entity 6860 | GrantStock Option (Right to Buy) · Derivative | 70,200 | $0.00 Strike: $1.55 | $0.00 |
DisclosureSEC source: 0000950170-24-099073 · ownership.xml · derivative · entry 1 Klickstein Lloyd · CIK 0001776004 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,200 Underlying: Common Stock · 70,200 shares Expires 2034-08-18 F1 · derivative.exercise_date: These shares shall vest in thirty-six (36) equal monthly installments following August 19, 2024; provided, however, that all vesting shall cease if the Reporting Person resigns from the Issuer's Board of Directors or otherwise ceases to serve as a director of the Issuer. Read SEC document |
| February 12, 2021 Filed Feb 18, 2021 02:16 UTC | Adicet Bio, Inc. ACET · Entity 6860 | GrantStock Option (Right to Buy) · Derivative | 41,100 | $0.00 Strike: $16.82 | $0.00 |
DisclosureSEC source: 0000899243-21-007031 · doc4.xml · derivative · entry 1 Klickstein Lloyd · CIK 0001776004 · Chief Innovation Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,100 Underlying: Common Stock · 41,100 shares Expires 2031-02-11 F1 · derivative.exercise_date: 1/48th of the shares shall vest on each of the next forty-eight (48) monthly anniversaries of the Vesting Commencement date, provided that the Reporting Person remains in continuous service as of the applicable vesting dates. Read SEC document |
| January 13, 2021 Filed Jan 15, 2021 21:30 UTC | Adicet Bio, Inc. ACET · Entity 6860 | GrantStock Option (Right to Buy) · Derivative | 80,000 | $0.00 Strike: $13.27 | $0.00 |
DisclosureSEC source: 0000899243-21-002194 · doc4.xml · derivative · entry 1 Klickstein Lloyd · CIK 0001776004 · Chief Innovation Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires 2031-01-12 F1 · derivative.exercise_date: 1/48th of the shares shall vest on each of the next forty-eight (48) monthly anniversaries of the Vesting Commencement date, provided that the Reporting Person remains in continuous service as of the applicable vesting dates. Read SEC document |
| October 23, 2020 Filed Mar 19, 2021 00:48 UTC | Adicet Bio, Inc. ACET · Entity 6860 | Tax withholdingCommon Stock | 4,957 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-012680 · doc4.xml · nonDerivative · entry 2 Klickstein Lloyd · CIK 0001776004 · Chief Innovation Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,931 F3 · shares: The Reporting Person is disposing of 4,957 restricted stock units as a result of a revised tax rate for such restricted stock units Read SEC document |
| September 17, 2020 Filed Sep 18, 2020 01:55 UTC | Adicet Bio, Inc. ACET · Entity 6860 | GrantStock Option (Right to Buy) · Derivative | 193,027 | $0.00 Strike: $16.11 | $0.00 |
DisclosureSEC source: 0000899243-20-025652 · doc4.xml · derivative · entry 1 Klickstein Lloyd · CIK 0001776004 · Chief Innovation Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 193,027 Underlying: Common Stock · 193,027 shares Expires 2030-09-16 F1 · derivative.exercise_date: 1/48th of the shares shall vest on each of the next forty-eight (48) monthly anniversaries. Read SEC document |
| December 06, 2019 Filed Dec 6, 2019 22:24 UTC | Adicet Bio, Inc. TORC · Entity 6860 | GrantStock Option (Right to Buy) · Derivative | 88,667 | $0.00 Strike: $1.27 | $0.00 |
DisclosureSEC source: 0000899243-19-028705 · doc4.xml · derivative · entry 2 Klickstein Lloyd · CIK 0001776004 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,667 Underlying: Common Stock · 88,667 shares Expires 2029-12-05 F2 · derivative.exercise_date: 25% of the shares shall vest on December 6, 2020, with the remainder vesting in 36 equal monthly installments thereafter. Read SEC document |
| December 06, 2019 Filed Dec 6, 2019 22:24 UTC | Adicet Bio, Inc. TORC · Entity 6860 | GrantCommon Stock | 118,222 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-028705 · doc4.xml · nonDerivative · entry 1 Klickstein Lloyd · CIK 0001776004 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,222 F1 · shares: The Reporting Person was issued Restricted Stock Units ("RSU"). Each RSU represents a contingent right to receive one share of common stock. The RSUs shall vest in four (4) annual installments, with the first tranche vesting on December 6, 2020. The RSUs may be settled only by delivering shares of common stock, and thus, the grant is being reported in Table I as allowed per SEC guidance. Read SEC document |
| December 06, 2019 Filed Mar 19, 2021 00:48 UTC | Adicet Bio, Inc. ACET · Entity 6860 | GrantCommon Stock | 16,888 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-012680 · doc4.xml · nonDerivative · entry 1 Klickstein Lloyd · CIK 0001776004 · Chief Innovation Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,888 F1 · shares: The Reporting Person was issued Restricted Stock Units ("RSU"). Each RSU represents a contingent right to receive one share of common stock. The RSUs shall vest in four (4) annual installments, with the first tranche vesting on December 6, 2020. The RSUs may be settled only by delivering shares of common stock, and thus, the grant is being reported in Table I as allowed per SEC guidance F2 · shares: The amount of securities reported herein have been adjusted to reflect the 1-for-7 reverse stock split that was effected in September 2020 in connection with the merger of resTORbio, Inc. and Adicet Therapeutics, Inc., formerly known as Adicet Bio, Inc. F2 · balance_after: The amount of securities reported herein have been adjusted to reflect the 1-for-7 reverse stock split that was effected in September 2020 in connection with the merger of resTORbio, Inc. and Adicet Therapeutics, Inc., formerly known as Adicet Bio, Inc. Read SEC document |
| May 13, 2019 Filed May 15, 2019 20:21 UTC | Adicet Bio, Inc. TORC · Entity 6860 | GrantStock Option (Right to Buy) · Derivative | 295,000 | $0.00 Strike: $8.08 | $0.00 |
DisclosureSEC source: 0000899243-19-013558 · doc4.xml · derivative · entry 1 Klickstein Lloyd · CIK 0001776004 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 295,000 Underlying: Common Stock · 295,000 shares Expires 2029-05-12 F1 · derivative.exercise_date: 25% of the shares shall vest on May 13, 2020, and the remaining shares shall vest in 12 equal quarterly installments thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.